ir.celgene.comInvestor relations - Bristol Myers Squibb

Our medicines Our stories Investors Contact us Careers United States Close Icon Americas Argentina Spanish Brazil Portuguese Canada English French Chile Spanish Colombia Spanish Mexico Spanish Peru Spanish United States English Asia Pacific Australia English China Simplified Chinese India English Japan Japanese Korea Korean New Zealand English Singapore English Taiwan Traditional Chinese Thailand English Thai Europe Austria German Belgium English Dutch French Czech Republic Czech Denmark Danish Finland Finnish France French Germany German Greece Greek Hungary Hungarian Ireland English Italy Italian Luxembourg English Netherlands English Dutch Norway Norwegian Poland Polish Portugal Portuguese Romania Romanian Spain Spanish Sweden Swedish Switzerland German French United Kingdom English Middle East Israel Hebrew Saudi Arabia English Arabic Turkey Turkish United Arab Emirates English Arabic Other Other Markets Distributor Markets bmsUScqPageLucene MedicinesCareersPress ReleasesMedical InformationPrevious Page Icon Previous Page Icon Our Medicines Patients & caregivers Next Page Icon Patients & caregivers Our medicines Get help paying for your medicines Patient resources Risk evaluation and mitigation strategies (REMS) QUICK LINKS Immunology patient resources Our position on generic drugs Our position on drug pricing Psoriasis around the world Healthcare providers Next Page Icon Healthcare providers Learn about pre-approval access Learn about post study drug access 340B practice fact sheet QUICK LINKS U.S. medical information Clinical trials Pre-approval access request system Post study drug access request system Researchers Next Page Icon Researchers Areas of focus In the pipeline R&D expert voices Our efforts in STEM Clinical trials & research Independent research The Thomas O. Daniel research incubator and collaboration center QUICK LINKS Perspectives from our head of research Research publications Disclosure commitment Investigator sponsored research portal Areas of interest & competitive research grants Compound & technology requests Data sharing request process Translational medicine Investors Next Page Icon Investors Stock information Financial reporting Analyst coverage Events and presentations Shareholder services Acquisition-related information for Celgene shareholders Investor contacts QUICK LINKS Annual report 2023 Dividend history Stock split history Investment return calculator SEC filings Quarterly results Product sales summary Annual reports archive Annual meeting of shareholders Business development Next Page Icon Business development Our partnerships Why partner with us Areas of interest Business development leadership team Begin a discussion Early innovation at BMS QUICK LINKS Download business development brochure "Golden Ticket" contests News Next Page Icon News Press releases Our stories Medical meetings Media library Media contacts QUICK LINKS Scientific media resources Disease state infographics Corporate publicationsNext Page IconOur company Leadership Global Inclusion & Diversity Responsibility Sustainability at Bristol Myers Squibb Contact us QUICK LINKS Global Patient Week Survivorship Today Our technologies History timeline Worldwide locations The Bristol Myers Squibb Foundation People & Business Resource groups Our commitment to global inclusion and diversity Position on key issues Investors Learn more about how we strive to produce sustained strong performance and shareholder value. NYSE : BMY N/A N/A N/A Change N/A Volume N/A Open See Detailed Stock Info (20 MIN DELAY) Explore investors Stock informationFinancial reportingAnalyst coverageEvents and presentationsShareholder servicesOnline delivery of shareholder materialsInvestor contactsUpcoming events View all There are currently no events scheduled. Recent events View all There are currently no events scheduled. Our stories View allBiking the globe for C2C4CDreaming big and trusting in talent: Getting to know John LovesethVoices from R&D: personal experience inspires the development of new medicinesLatest press releases View more Subscribe to Press Release Email AlertsOur reports Annual reportGlobal inclusion and diversity reportEnvironmental, social and governance reportGlobal access reportOur science We are guided by a single vision Transforming patients’ lives through science Our pipeline is focused on research in therapeutic areas where we believe we have the best opportunity to deliver transformational medicines to patients. Our R&D pipeline Investor resources Tool kit Investment return calculatorCost basis calculatorSEC filingsAnnual reports Interactive annual reportAnnual report requestView past annual reportsShareholder services Buy sharesCheck your accountRead FAQs for BMY shareholdersRead acquisition FAQs for Celgene shareholdersRead FAQs for Mirati shareholdersAbraxane CVR notificationEmail alerts Click investor alerts to manage event, presentation and SEC Filing email notifications, or select press release alerts to subscribe to company news alerts. Investor alertsPress release alertsBusiness Development information BMS completes global license deal with SystImmune Learn MoreFAQs for Mirati shareholders Frequently asked questions about Mirati Learn MoreFAQs for Celgene shareholders Frequently asked questions about Celgene shares and CVRs. Learn MoreTax information for Celgene shareholders Information including IRS Form 8937. Learn MoreMaterials on this website may contain information about the Company’s future plans and prospects that constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Forward-looking statements contained on this website should be evaluated together with the many uncertainties that affect Bristol Myers Squibb’s business, particularly those identified in the cautionary factors discussion in the company’s most recent annual report on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. These documents are available from the Securities and Exchange Commission, the Bristol Myers Squibb website or from Bristol Myers Squibb Investor Relations. In addition, any information contained on this website was current as of the date presented and should not be relied upon as representing our estimates as of any subsequent date. While we may elect to update forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our estimates change, whether as a result of new information, future events or otherwise. Consequently, the company will not update the information contained on the website and investors should not rely upon the information as current or accurate after the presentation date. The website may also contain certain non-GAAP financial measures, adjusted to exclude certain costs, expenses, gains and losses and other specified items. Reconciliations of these non-GAAP financial measures to the most comparable GAAP measures for a particular quarterly period are available on the company’s website at www.bms.com .​​​ Main navigation Home Patients & caregivers Healthcare providers Researchers Investors NewsResources Our medicines Legal notice Privacy notice Trademarks Forward-looking statement UK-CA slavery and human trafficking statement (PDF) Follow us Careers Our stories Contact us Worldwide locations April 17, 2024 © 2024 Bristol-Myers Squibb...